BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21298351)

  • 1. Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery.
    Lee JM; Yang SY; Yang PW; Shun CT; Wu MT; Hsu CH; Lin CC; Cheng JC; Wang YH; Chuang TH; Chen JS; Hsu HH; Huang PM; Kuo SW; Lee YC
    Ann Surg Oncol; 2011 Jul; 18(7):2066-73. PubMed ID: 21298351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.
    Hsu FM; Lee JM; Huang PM; Lin CC; Hsu CH; Tsai YC; Lee YC; Chia-Hsien Cheng J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e593-9. PubMed ID: 21658851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 -330T>G genetic polymorphism associates with prognosis following surgery for thoracic esophageal squamous cell cancer.
    Motoyama S; Miura M; Hinai Y; Maruyama K; Usami S; Yoshino K; Nakatsu T; Saito H; Minamiya Y; Ogawa J
    Ann Surg Oncol; 2011 Jul; 18(7):1995-2002. PubMed ID: 21258967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
    Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
    J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
    Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
    Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
    Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
    Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of germline polymorphisms in predicting concurrent chemoradiotherapy response in esophageal cancer.
    Chen PC; Chen YC; Lai LC; Tsai MH; Chen SK; Yang PW; Lee YC; Hsiao CK; Lee JM; Chuang EY
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1996-2003. PubMed ID: 21596488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
    Makino T; Yamasaki M; Miyata H; Yoshioka S; Takiguchi S; Fujiwara Y; Nakajima K; Nishida T; Mori M; Doki Y
    Ann Surg Oncol; 2010 Mar; 17(3):804-11. PubMed ID: 19885698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer.
    Motoori M; Yano M; Ishihara R; Yamamoto S; Kawaguchi Y; Tanaka K; Kishi K; Miyashiro I; Fujiwara Y; Shingai T; Noura S; Ohue M; Ohigashi H; Nakamura S; Ishikawa O
    Ann Surg Oncol; 2012 Jul; 19(7):2135-41. PubMed ID: 22302264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent chemoradiotherapy for locally advanced esophageal cancer--a pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil.
    Hsu CH; Yeh KH; Lui LT; Lee YC; Bu CF; Wang HP; Lin JT; Cheng AL
    Anticancer Res; 1999; 19(5C):4463-7. PubMed ID: 10650793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
    Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The survival impact of XPA and XPC genetic polymorphisms on patients with esophageal squamous cell carcinoma.
    Yang PW; Hsieh CY; Kuo FT; Huang PM; Hsu HH; Kuo SW; Chen JS; Lee JM
    Ann Surg Oncol; 2013 Feb; 20(2):562-71. PubMed ID: 22941172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multivariate prognostic analysis for patients with unresectable esophageal carcinoma after concurrent chemoradiotherapy].
    Chen EC; Liu MZ; Hu YH; Li QQ; Liu H; Cai L; Liu H; Lin HX; Huang Y; Wang HY; Cui NJ
    Ai Zheng; 2005 Jun; 24(6):731-4. PubMed ID: 15946490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
    Watanabe M; Baba Y; Yoshida N; Ishimoto T; Nagai Y; Iwatsuki M; Iwagami S; Baba H
    Ann Surg Oncol; 2014 Sep; 21(9):2838-44. PubMed ID: 24715216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy.
    Motoyama S; Sugiyama T; Ueno Y; Okamoto H; Takasawa S; Nanjo H; Watanabe H; Maruyama K; Okuyama M; Ogawa J
    Ann Surg Oncol; 2006 Dec; 13(12):1724-31. PubMed ID: 17009160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma.
    Akutsu Y; Hanari N; Yusup G; Komatsu-Akimoto A; Ikeda N; Mori M; Yoneyama Y; Endo S; Miyazawa Y; Matsubara H
    Ann Surg Oncol; 2011 Oct; 18(10):2946-51. PubMed ID: 21437756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation.
    Zhang W; Park DJ; Lu B; Yang DY; Gordon M; Groshen S; Yun J; Press OA; Vallböhmer D; Rhodes K; Lenz HJ
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):600-5. PubMed ID: 15701846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.